<DOC>
	<DOCNO>NCT02744768</DOCNO>
	<brief_summary>This study aim explore activity frontline approach base dasatinib plus steroids administration induction treatment , follow infusion Blinatumomab , adult Ph+ ALL .</brief_summary>
	<brief_title>D-ALBA Frontline Sequential Dasatinib Blinatumomab Adult Philadelphia Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Newly diagnose adult Bprecursor Ph+ ALL patient . Age great equal to18 year , Signed write informed consent accord ICH/EU/GCP national local law . ECOG Performance Status 0 1 and/or WHO performance status less equal 2 . Renal hepatic function define : AST ( GOT ) , ALT ( GPT ) , AP &lt; 2 x upper limit normal ( ULN ) . Total bilirubin &lt; 1.5 x ULN . Creatinine clearance equal great 50 mL/min . Pancreatic function define : Serum amylase less equal 1.5 x ULN Serum lipase less equal to1.5 x ULN . Normal cardiac function . Negative HIV test , negative HBV DNA HCV RNA . Negative pregnancy test woman childbearing potential . Bone marrow specimen primary diagnosis available . History current relevant CNS pathology ( current â‰¥grade 2 epilepsy , seizure , paresis , aphasia , clinically relevant apoplexia , severe brain injury , dementia , Parkinson 's disease , organic brain syndrome , psychosis ) . Impaired cardiac function , include one following : LVEF &lt; 45 % determine MUGA scan echocardiogram . Complete leave bundle branch block . Use cardiac pacemaker . ST depression &gt; 1mm 2 lead and/or T wave inversion 2 contiguous lead . Congenital long QT syndrome . History presence significant ventricular atrial arrhythmia . Clinically significant rest bradycardia ( &lt; 50 beat per minute ) . QTc &gt; 450 msec screen ECG ( use QTcF formula ) . Right bundle branch block plus leave anterior hemiblock , bifascicular block . Myocardial infarction within 3 month prior start Dasatinib . Angina pectoris . Other clinically significant heart disease ( e.g. , congestive heart failure , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption Dasatinib ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . History current autoimmune disease . Systemic cancer chemotherapy within 2 week prior study . Known hypersensitivity immunoglobulins component study drug formulation . Active malignancy ALL exception basal cell squamous cell carcinoma skin , carcinoma `` situ '' cervix . Active infection , concurrent disease medical condition deem interfere conduct study judge investigator . Nursing woman woman childbearing potential willing use effective form contraception participation study least 3 month thereafter male patient willing ensure effective contraception participation study least three month thereafter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia , adult , dasatinib , blinatumomab</keyword>
</DOC>